Clinical characteristics and analysis of treatment result in children with Ph-positive acute lymphoblastic leukaemia in Poland between 2005 and 2017

European Journal of Haematology
Joanna ZawitkowskaJerzy Kowalczyk

Abstract

The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL. A total of 2591 newly diagnosed ALL children were treated in Poland between the years 2005 and 2017. Of those, 44 were diagnosed with Ph(+) ALL. The patients were treated according to protocols: ALL IC-BFM 2002 and 2009 (26 patients), EsPhALL (12 patients), initially ALL IC-BFM and then EsPhALL (6 patients). The median of follow-up in the observed group was 3 years. Overall survival (OS) and event-free survival (EFS) of Ph+ ALL group were 0.73 and 0.64. OS and EFS of patients after HSCT were 0.78 and 0.66, while without HSCT were 0.6 and 0.6, P = 0.27 and 0.63. OS was 0.8 for patients treated with chemotherapy plus imatinib and 0.61 for chemotherapy alone, P = 0.22, while EFS was 0.66 (imatinib therapy) and 0. 61 (without imatinib), P = 0.41. Our study suggests that adding imatinib to intensive chemotherapy seems to improve outcome. However, this study was limited by a small number of patients and a variety of chemotherapy regimens with or without imatinib.

References

Aug 16, 2005·British Journal of Haematology·Louise K Jones, Vaskar Saha
Jul 22, 2009·Pediatric Blood & Cancer·Michael J BurkeRichard Kadota
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirk R SchultzBruce Camitta
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan StaryMartin Schrappe
Dec 25, 2013·Blood·Arian van der VeerGiovanni Cazzaniga
Mar 6, 2015·Haematologica·Veronica Leoni, Andrea Biondi
May 2, 2015·Journal of Pediatric Hematology/oncology·Ryoko SuzukiTakashi Fukushima
Jun 9, 2017·Korean journal of pediatrics·Jae Wook Lee, Bin Cho
Mar 10, 2018·Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University·Małgorzata Janeczko-CzarneckaKrzysztof Kałwak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.